Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Intellia Therapeutics

Intellia Therapeutics Stock Is Down Nearly 95% From Its Record Highs but Cathie Wood Keeps Buying

Despite Intellia's severe stock drop from its 2021 peak, Cathie Wood is buying big.

Intellia Therapeutics Pops on CRISPR Trial Success. Does That Make NTLA Stock a Buy?

Intellia Therapeutics Pops on CRISPR Trial Success. Does That Make NTLA Stock a Buy?

Intellia Therapeutics stock soars on promising Phase 3 results for its hereditary angioedema (HAE) candidate. But is there any further upside left in NTLA shares?

Should You Buy the Dip in Intellia Therapeutics Stock?

Should You Buy the Dip in Intellia Therapeutics Stock?

A patient’s death shook Intellia Therapeutics and sank its stock. Should investors buy the dip or steer clear?

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Is This Beaten-Down Cathie Wood Stock Still a Buy?

Intellia’s shares plunged 23% after its Q3 results showed a pipeline setback. Nonetheless, Cathie Wood’s stake in the company is expanding.

This Boot Barn Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles

Intellia Therapeutics Inc. (NASDAQ:NTLA) shares tumbled after the company said it had temporarily paused patient dosing and screening in its Phase 3 MAGNITUDE and MAGNITUDE-2 trials of its experimental CRISPR therapy, nexiguran ziclumeran (nex-z), following a serious liver-related adverse event in one participant.

Intellia Therapeutics Shares Are Ripping Higher: Here's Why

Intellia Therapeutics Inc (NASDAQ:NTLA) shares are soaring on Thursday after the company completed enrollment in its crucial Phase 3 HAELO trial and laid out its key development milestones.

inkl

Read news from The Economist, FT, and more,
with one subscription

Cathie Wood Is Betting Big on Intellia Therapeutics. Should You Buy NTLA Stock Here?

Cathie Wood Is Betting Big on Intellia Therapeutics. Should You Buy NTLA Stock Here?

Cathie Wood recently acquired shares of the biotech company. Should you do the same?

Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook

Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook

Goldman Sachs raised its year-end S&P 500 forecast and identified three stocks that are poised to outperform in the second half of 2025: KSS, NTLA, and GOGO.

2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street

2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street

These biotech companies’ strategic advancements are setting them up for long-term success.

This Cathie Wood Stock Can Soar 221%, Says Wall Street

This Cathie Wood Stock Can Soar 221%, Says Wall Street

Promising clinical trial results have analysts optimistic about the company’s future.

3 Cathie Wood Biotech Stocks That Analysts Expect to Double

3 Cathie Wood Biotech Stocks That Analysts Expect to Double

This article delves into three biotech stocks held in Cathie Wood's ARKK ETF that analysts expect to double in value. Investors looking to add exposure to promising biotech opportunities, with a preference for Wood's disruptive approach to investing, may find these stocks particularly compelling.

'This is the future': ACT trials gene-editing to treat heart patient

'This is the future': ACT trials gene-editing to treat heart patient

The technology is literally 'cutting' edge.

The Canberra Times

1

People

Walter Abhayaratna

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Canberra Hospital

ARK Innovation ETF

Intellia Therapeutics

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play